Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | NCF1 | P14598 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12717742 | 0.81 | KDM1A (0.43) | KDM1ANCF1ALDH1A1L3MBTL1ALOX15 | |
| SCHEMBL25001502 | 0.79 | — | — | |
| SCHEMBL24204754 | 0.78 | KDM1A (0.41) | KDM1ANCF1ALDH1A1L3MBTL1ALOX15 | |
| SCHEMBL24828028 | 0.78 | KDM1A (0.41) | KDM1ANCF1ALDH1A1L3MBTL1ALOX15 | |
| SCHEMBL22737333 | 0.78 | KDM1A (0.41) | KDM1ANCF1ALDH1A1L3MBTL1ALOX15 | |
| SCHEMBL15038030 | 0.77 | — | — | |
| SCHEMBL25922263 | 0.77 | KDM4E (0.35) | ALDH1A1ALOX15 | |
| SCHEMBL25921507 | 0.77 | KDM4E (0.35) | ALDH1A1ALOX15 | |
| SCHEMBL25921506 | 0.77 | KDM4E (0.35) | ALDH1A1ALOX15 | |
| SCHEMBL22695351 | 0.76 | KDM1A (0.40) | KDM1ANCF1ALDH1A1L3MBTL1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219986-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | QILU PHARMACEUTICAL CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
| US-20230219986-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | QILU PHARMACEUTICAL CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219986-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | EGFR, ERBB2, ERBB4 | KDM1A 2608/4885NCF1 1273/4885ALDH1A1 2690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.